Cardiovascular aspects of psoriasis: An updated review

International Journal of Dermatology

Volumn 52, Issue 2, 2013, Pages 153-162

  Pietrzak, Aldona ^a   Bartosińska, Joanna ^a   Chodorowska, Graz̊yna ^a   Szepietowski, Jacek C ^b   Paluszkiewicz, Piotr ^a,c   Schwartz, Robert A ^d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Lublin Cancer Centre   (Poland)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE SEVERITY; EMBASE; HEART DISEASE; HUMAN; INSULIN RESISTANCE; LIFE EXPECTANCY; MEDLINE; MORBIDITY; PSORIASIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL;

ATHEROSCLEROSIS; HUMANS; PSORIASIS; RISK FACTORS;

EID: 84873043844     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05584.x     Document Type: Review

References (86)

1. Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7.
2. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007; 57: 347-354.
3. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2009; 24: 22-27.
4. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol 2011; 64: 495-501.
5. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol 2011; 146: 9-15.
6. Chen YJ, Shen JL, Wu CY, et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009; 60: 225-230.
7. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 52-55.
8. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475.
9. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
10. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
11. Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
12. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
13. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
14. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.
15. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
16. Altobelli E, Petrocelli R, Maccarone M, et al. Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on sociodemographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009; 19: 252-256.
17. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218.
18. Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep 2009; 1: 30.
19. Kerekes G, Soltész P, Dér H, et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009; 1173: 814-821.
20. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-2912.
21. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-872.
22. Federman DG, Shelling M, Prodanovich S, et al. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 160: 1-7.
23. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
24. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157.
25. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The "psoriatic march": a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
26. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251.
27. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-289.
28. Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159(Suppl. 2): 10-17.
29. Markuszeski L, Bissinger A, Janusz I, et al. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res 2007; 38: 64-69.
30. Acevedo M, Corbalán R, Braun S, et al. C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia". Int J Cardiol 2006; 108: 326-331.
31. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-422.
32. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006; 17: 699-706.
33. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-183.
34. de Beer FC, Hind CR, Fox KM, et al. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J 1982; 47: 239-243.
35. Tobin AM, Kirby B. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 161: 719.
36. Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther 2010; 23: 144-151.
37. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634.
38. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164: 26-32.
39. Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
40. Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.
41. Cakmak SK, Gül U, Kiliç C, et al. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol 2009; 23: 300-303.
42. Malerba M, Gisondi P, Radaeli A, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165-1169.
43. Friedewald VE, Cather JC, Gelfand JM, et al. AJC editors' consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631-1643.
44. Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48: 379-387.
45. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
46. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24: 23-30.
47. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
48. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
49. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
50. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-424.
51. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
52. Murray ML, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol 2009; 34: 140-144.
53. Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-826.
54. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
55. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-1367.
56. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?Am J Med 2005; 118: 816-826.
57. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-292.
58. Reed WB, Becker SW, Rohde R, Heiskell CL. Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol 1961; 83: 541-548.
59. McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch Dermatol 1973; 107: 918.
60. Vlaanderen J, Vermeulen R, Heederik D, Kromhout H. Guidelines to evaluate human observational studies for quantitative risk assessment. Environ Health Perspect 2008; 116: 1700-1705.
61. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
62. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
63. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008; 217: 27-37.
64. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010; 130: 919-922.
65. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011; 131: 1007-1010.
66. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
67. Yalcin H, Balci DD, Ucar E, et al. Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. J Eur Acad Dermatol Venereol 2009; 23: 798-802.
68. Tarek AS, Said HT Atherosclerotic risk in psoriasis. J PALD 2005; 16: 39-45.
69. El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2009; 24: 661-666.
70. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009; 218: 110-113.
71. Yiu KH, Yeung CK, Chan HT, et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164: 514-520.
72. Günes Y, Tuncer M, Guntekin U, et al. Increased P wave dispersion in patients with psoriasis. Türk J Cardiol 2007; 10: 154-159.
73. Mastrolonardo M, Picardi A, Alicino D, et al. Cardiovascular reactivity to experimental stress in psoriasis: a controlled investigation. Acta Derm Venereol 2006; 86: 340-344.
74. Carvalho M, Soares R, Ribeiro F, et al. Rhythm profile in patients with psoriatic arthritis. Rev Port Cardiol 1990; 9: 311-317.
75. Jha PK, Das SR, Musleh GS, et al. Psoriasis-induced postoperative cardiac failure. Ann Thorac Surg 2005; 79: 1390-1391.
76. Eliakim-Raz N, Shuvy M, Lotan C, Planer D. Psoriasis and dilated cardiomyopathy: coincidence or associated diseases?Cardiology 2008; 111: 202-206.
77. Fukuhara K, Urano Y, Akaike M, et al. Psoriatic arthritis associated with dilated cardiomyopathy and Takayasu's arteritis. Br J Dermatol 1998; 138: 329-333.
78. Shang Q, Tam LS, Yip GW, et al. High prevalence of subclinical left ventricular dysfunction in patients with psoriatic arthritis. J Rheumatol 2011; 38: 1363-1370.
79. Menter A, Griffiths CE, Tebbey PW, et al. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol 2010; 24: 1371-1377.
80. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331.
81. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
82. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-373.
83. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
84. Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-432.
85. Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE 2011; 6: e18125.
86. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 1-6.